Core Viewpoint - The Schall Law Firm is investigating claims against Abacus Global Management, Inc. for potential violations of securities laws, focusing on misleading statements and undisclosed information [1][2]. Group 1: Investigation Details - The investigation centers on whether Abacus issued false or misleading statements and failed to disclose critical information to investors [2]. - A report by Morpheus Research dated June 4, 2025, claims that Abacus, valued at $794 million, altered its portfolio valuation methodology to present a more favorable financial picture [2]. - The report also suggests that Abacus employs unusual methods for calculating life expectancy estimates and highlights past concerns regarding its co-founders [2]. Group 2: Legal Representation - The Schall Law Firm invites shareholders who have experienced losses to participate in the investigation and offers free consultations regarding their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Insights - Marsh & McLennan Companies, Inc.'s (MMC) arm, Marsh, released a global cybersecurity report indicating that 75% of organizations are "highly confident" in their cyber-risk management strategies, with significant regional variations [1][9] - The report highlights that 66% of respondents plan to increase cybersecurity investments in the next year, with 26% expecting budget increases of 25% or more [2][9] - The findings suggest a shift in perception, positioning cybersecurity as a core business priority rather than just an IT issue, driven by the prevalence of third-party incidents and ransomware concerns [3][9] Investment Priorities - The top investment priorities identified in the report include cybersecurity technologies and mitigation tools, incident-response planning, and hiring security talent [2] - The report indicates that 70% of organizations experienced at least one major third-party cybersecurity incident in the past year, underscoring the need for enhanced security measures [2] Strategic Positioning - For MMC, the report positions the company as a trusted advisor in the growing global demand for cybersecurity risk management, potentially leading to increased service demand and higher premiums [4] - As organizations allocate higher budgets to cyber-defense, MMC could see revenue growth in its risk advisory and insurance brokerage lines [4] Financial Estimates - The Zacks Consensus Estimate for MMC's revenues indicates a 10% increase for 2025 and a 4.7% increase for 2026, with EPS estimates of $9.61 for 2025 (9.2% growth) and a further 6.9% increase for 2026 [5] - MMC has consistently beaten earnings estimates in the past four quarters, with an average surprise of 3.5% [5]

Core Insights - Abacus Global Management, Inc. (NASDAQ: ABL) is recognized as one of the best life insurance stocks to invest in currently [1] - Northland Securities analyst Michael Grondahl maintains a bullish outlook on Abacus Life, Inc., reaffirming a buy rating with a price target of $13.50 [2] - The company announced its first-ever annual cash dividend of $0.20 per share, set to be paid on December 17, 2025, to shareholders of record as of December 2, 2025 [3] Financial Performance - For Q3, Abacus Global Management reported non-GAAP earnings per share of $0.24, exceeding projections by $0.06, with revenue of $63 million surpassing expectations by $15.58 million, reflecting a year-on-year revenue increase of 124.2% [5] - The company's dividend policy allows for payouts of up to 25% of adjusted net income or 55% of recurring revenue, supported by record cash creation, higher fee-based revenue, and growing margins [4] Business Focus - Abacus Global Management specializes in institutional services, life solutions, data-driven wealth solutions, and alternative asset management [6]

Industry Overview - Fitch Ratings maintains a 'neutral' outlook for the North American life insurance sector in 2026, citing solid balance sheets as a partial offset to slower economic growth and increased macroeconomic volatility [2][4] - Life insurers are expected to maintain strong capitalization and careful asset-liability management despite higher exposure to private credit, with investment risk likely to rise slightly [2][4] - The regulatory environment is dynamic, focusing on capital adequacy relative to risk, with strong capitalization mitigating market susceptibility [3] Financial Performance - Operating profits are projected to remain unchanged, with spread widening expected to increase net investment income, although policy rate cuts may slightly offset this benefit [4] - Primerica, Inc. reported adjusted net operating income of $206 million for Q3 2025, up 7% year over year, with EPS increasing by 11% to $6.33 [16] - Abacus Global Management, Inc. reported Q3 non-GAAP earnings per share of $0.24, exceeding projections by $0.06, and revenue of $63 million, which was $15.58 million above expectations, reflecting a 124.2% year-on-year increase [12] Investment Opportunities - The article lists the 9 Best Life Insurance Stocks to Buy Now, focusing on stocks with strong hedge fund holdings and potential upside [5][7] - Abacus Global Management, Inc. has a significant upside potential of 98.13% as of December 4, 2025, with a buy rating reaffirmed by analysts [9] - Primerica, Inc. has a potential upside of 19.97%, with a consensus 1-year median price target of $303, despite a cautious outlook from analysts [14]

Group 1 - U.S. stock futures are higher, with Dow futures gaining around 50 points [1] - Tilray Brands Inc announced a one-for-10 reverse stock split, effective December 1 [1] - Tilray shares fell sharply by 15% to $0.88 in pre-market trading [2] Group 2 - Inventiva ADR fell 7.4% to $4.26 in pre-market trading after a previous gain [4] - Anglogold Ashanti PLC dipped 5.5% to $83.97 in pre-market trading after a gain of over 5% [4] - Lexicon Pharmaceuticals Inc fell 5% to $1.36 in pre-market trading [4] - SuperX AI Technology Ltd fell 3.9% to $26.00 in pre-market trading after a significant previous jump of 23% [4] - Palisade Bio Inc declined 3.6% to $2.15 in pre-market trading [4] - Gold Fields Ltd fell 3.4% to $41.76 in pre-market trading after a gain of 6% [4] - Abacus Global Management Inc fell 3.2% to $6.33 in pre-market trading after reporting better-than-expected third-quarter results and announcing a $10 million buyback [4]

Group 1 - U.S. stock futures are higher, with Dow futures gaining approximately 50 points [1] - Tilray Brands Inc shares fell sharply by 15% to $0.88 in pre-market trading after announcing a one-for-10 reverse stock split [2][1] - The reverse stock split for Tilray was approved in June and will take effect on December 1 [1] Group 2 - Inventiva ADR shares decreased by 7.4% to $4.26 in pre-market trading after a previous gain of 4% [4] - Anglogold Ashanti PLC shares dipped by 5.5% to $83.97 after gaining over 5% on Wednesday [4] - Lexicon Pharmaceuticals Inc shares fell by 5% to $1.36 in pre-market trading [4] - SuperX AI Technology Ltd shares declined by 3.9% to $26.00 after a significant increase of 23% on Wednesday due to a $20 million share repurchase program announcement [4] - Palisade Bio Inc shares decreased by 3.6% to $2.15 in pre-market trading [4] - Gold Fields Ltd shares fell by 3.4% to $41.76 after a 6% gain on Wednesday [4] - Abacus Global Management Inc shares declined by 3.2% to $6.33 after reporting better-than-expected third-quarter results and announcing a $10 million buyback [4]

Core Viewpoint - Abacus Global Management has reported its tenth consecutive quarter of earnings, showcasing consistent performance and growth in funding and origination capabilities, with a strong outlook into 2026 [1][2]. Financial Performance - Gross revenue increased by 124% year-over-year, while adjusted net income grew by 60% [2]. - The company has achieved earnings beats greater than 30% in six of the last ten quarters, indicating sustained performance [2]. Business Model and Strategy - Abacus operates as an active management company, monetizing contracts and policies on its balance sheet with strong margins of around 37% [3]. - The company has raised nearly $500 million in new capital this year, driven by strong institutional interest in uncorrelated yield [3]. Revenue Composition - 15% of Abacus's revenue is now recurring, and the recently launched dividend represents just over 20% of adjusted net income, allowing for capital return to shareholders while maintaining a return on equity (ROE) over 20% [4]. Recent Acquisitions - The acquisition of AccuQuote enhances client lifecycle coverage, enabling the company to offer better-suited policies and convert previously unmonetized leads into product sales [5][6]. - AccuQuote brings 30 years of experience and $150 million in issued premium, providing both new policy sales and potential legacy contract value [6]. Securitization and Balance Sheet Strength - A recent $50 million securitized asset transaction strengthens the balance sheet and supports future growth through scalable and competitive rates [7][8]. - The participation of insurance companies and banks in this transaction validates the valuations and underlying assets, while the company earns servicing fees for five years [8]. Market Position and Investor Appeal - Being added to the Russell 2000 and 3000 indexes enhances Abacus's visibility, attracting more capital from ETFs and investors seeking strong companies [9]. - The company is now a dividend-paying stock with a yield between 3.5% and 4.5%, placing it in a selective group among Russell 2000 companies [10].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Motorsport Games Inc. (MSGM) has seen a substantial increase of 122%, trading at $4.88 [3] - Globus Medical, Inc. (GMED) is up 27%, currently priced at $78.75 [3] - JFrog Ltd. (FROG) has risen by 26%, trading at $59.60 [3] - FIGS, Inc. (FIGS) is up 19%, with a trading price of $8.97 [3] - Organogenesis Holdings Inc. (ORGO) has increased by 18%, trading at $4.59 [3] - PureCycle Technologies, Inc. (PCT) is up 17%, currently priced at $11.31 [3] - Expedia Group, Inc. (EXPE) has risen by 16%, trading at $255.10 [3] - 10x Genomics, Inc. (TXG) is up 13%, currently priced at $14.72 [3] - Abacus Global Management, Inc. (ABL) has increased by 12%, trading at $5.95 [3] - GigaCloud Technology Inc. (GCT) is up 9%, currently priced at $27.80 [3] Premarket Losers - Davis Commodities Limited (DTCK) has experienced a significant decline of 65%, trading at $2.23 [4] - Eledon Pharmaceuticals, Inc. (ELDN) is down 46%, currently priced at $2.19 [4] - Treace Medical Concepts, Inc. (TMCI) has decreased by 35%, trading at $4.00 [4] - Energys Group Limited (ENGS) is down 30%, currently priced at $2.77 [4] - Intellia Therapeutics, Inc. (NTLA) has seen a decline of 27%, trading at $8.89 [4] - Fox Factory Holding Corp. (FOXF) is down 24%, currently priced at $16.60 [4] - Opendoor Technologies Inc. (OPEN) has decreased by 24%, trading at $4.94 [4] - AirSculpt Technologies, Inc. (AIRS) is down 21%, currently priced at $8.27 [4] - Power Solutions International, Inc. (PSIX) has seen a decline of 20%, trading at $64.25 [4] - ClearPoint Neuro, Inc. (CLPT) is down 17%, currently priced at $15.00 [4]

Core Insights - Abacus Life, Inc. reported quarterly earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and matching the earnings from the previous year [1] - The company achieved revenues of $62.98 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 32.80% and significantly increasing from $28.15 million year-over-year [2] - The stock has underperformed, losing approximately 32.3% since the beginning of the year, while the S&P 500 has gained 15.6% [3] Earnings Performance - Abacus Life has surpassed consensus EPS estimates in all four of the last quarters [2] - The company had an earnings surprise of +11.11% for the latest quarter and a +37.5% surprise in the previous quarter [1][2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $50.49 million, and for the current fiscal year, it is $0.79 on revenues of $198.29 million [7] - The Zacks Rank for Abacus Life is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Insurance - Life Insurance industry is currently ranked in the top 11% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

Core Insights - Sun Life (SLF) reported quarterly earnings of $1.35 per share, exceeding the Zacks Consensus Estimate of $1.30 per share, and showing an increase from $1.29 per share a year ago, resulting in an earnings surprise of +3.85% [1] - The company posted revenues of $6.48 billion for the quarter ended September 2025, which was below the Zacks Consensus Estimate by 3.06%, but an increase from $6.29 billion year-over-year [2] - Sun Life's stock has increased by approximately 3.4% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.36, with expected revenues of $6.84 billion, and for the current fiscal year, the EPS estimate is $5.27 on revenues of $27.79 billion [7] - The estimate revisions trend for Sun Life was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Insurance - Life Insurance industry, to which Sun Life belongs, is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]